EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes

Andrea Mancini iD, Erik Stoops, Leentje Demeyer, Giovanni Bellomo, Federico Paolini Paoletti iD, Lorenzo Gaetani, Massimiliano Di Filippo, Lucilla Parnetti

Movement Disorders · 2023-04 · 38 (4) · 682-688

DOI: 10.1002/mds.29336 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 18.02.2023. Verfasst von Andrea Mancini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Dementia, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, Parkinsonian Disorders. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The alteration of leucine‐rich repeat kinase 2 (LRRK2) kinase activity is thought to be involved in Parkinson's disease (PD) pathogenesis beyond familiar cases, and LRRK2 inhibitors are currently under investigation. Preliminary data suggest a relationship between LRRK2 alteration and cognitive impairment in PD.

Objective

To investigate cerebrospinal fluid (CSF) LRRK2 levels in PD and other parkinsonian disorders, also correlating them with cognitive impairment.

Methods

In this study, we retrospectively investigated by means of a novel highly sensitive immunoassay the levels of total and phosphorylated (pS1292) LRRK2 in CSF of cognitively unimpaired PD (n = 55), PD with mild cognitive impairment (n = 49), PD with dementia (n = 18), dementia with Lewy bodies (n = 12), atypical parkinsonian syndromes (n = 35), and neurological controls (n = 30).

Results

Total and pS1292 LRRK2 levels were significantly higher in PD with dementia with respect to PD with mild cognitive impairment and PD, and also showed a correlation with cognitive performances.

Conclusions

The tested immunoassay may represent a reliable method for assessing CSF LRRK2 levels. The results appear to confirm an association of LRRK2 alteration with cognitive impairment in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DementiaLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson DiseaseParkinsonian DisordersHumansMutationRetrospective Studies

Stichwörter der Autor:innen

LRRK2Parkinson's diseaseatypical parkinsonian syndromescognitive impairment

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, human

Autor:innen und Institutionen

  • Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
  • ADx NeuroSciences NV, Gent, Belgium.
  • Laboratory of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

ORCID-Profile: Andrea Mancini, Federico Paolini Paoletti

Zitieren

APA

Mancini, A., Stoops, E., Demeyer, L., Bellomo, G., Paolini Paoletti, F., Gaetani, L., Di Filippo, M., & Parnetti, L. (2023). LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes. Movement Disorders, 38(4), 682-688. https://doi.org/10.1002/mds.29336

Vancouver

Mancini A, Stoops E, Demeyer L, Bellomo G, Paolini Paoletti F, Gaetani L, et al. LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes. Movement Disorders. 2023;38(4):682-688. doi:10.1002/mds.29336

BibTeX
@article{Mancini2023,
  author = {Mancini, Andrea and Stoops, Erik and Demeyer, Leentje and Bellomo, Giovanni and Paolini Paoletti, Federico and Gaetani, Lorenzo and Di Filippo, Massimiliano and Parnetti, Lucilla},
  title = {LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes},
  journal = {Movement Disorders},
  year = {2023},
  volume = {38},
  number = {4},
  pages = {682--688},
  doi = {10.1002/mds.29336}
}
Kostenlos starten →